Program

Saturday, October 15

Educational Session

Session Chairperson: Tona M. Gilmer, GlaxoSmithKline, Research Triangle Park, NC
1:00 p.m.-4:00 p.m.

Challenges in analyzing cancer genomes for clinical decisions
Gad Getz, Broad Institute, Cambridge, MA

Cancer genomics in the TCGA, TARGET, and ICGC projects
David Haussler, Howard Hughes Medical Institute, Santa Cruz, CA

Determinants of response and resistance in drug discovery and development
Tona M. Gilmer

Bridging the gap between cancer genomics and drug discovery
Giulio F. Draetta, University of Texas MD Anderson Cancer Center, Houston, TX

Applying massively parallel sequencing technology to the study of cancer genomes
Elaine Mardis, Washington University School of Medicine, St. Louis, MO

Session 1: Biology and Genomics of Cancer Evolution

Session Chairperson: Elaine Mardis, Washington University School of Medicine, St. Louis, MO
6:00 p.m.-8:00 p.m.

Evolution of the cancer genome
Elaine Mardis

Genomic compartmentalization of epigenetic alterations in cancer
Peter W. Laird, University of Southern California, Los Angeles, CA

Dealing with intra- and intertumoral heterogeneity
Gordon B. Mills, University of Texas MD Anderson Cancer Center, Houston, TX

Exome sequencing and integrative mutational profiling of lethal castrate resistant prostate cancer *
Catherine Grasso, Michigan Center for Translational Pathology, Ann Arbor, MI

Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells *
Yu Zhang, Harvard Medical School, Boston, MA

Welcome Reception

Sunday, October 16

Continental Breakfast

Keynote Presentation 1

Organizing large projects across boundaries: The particle physics experience
Pier J. Oddone, Fermilab, Batavia, IL

Session 2: Functional Genomics I

Session Chairperson: Scott W. Lowe, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
9:00 a.m.-11:00 a.m.

Functional genomics to decipher cancer dependencies and mechanisms
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA 

Constructing and deconstructing cancer using mouse models and RNA interference
Scott W. Lowe

Target discovery through functional genomics
Timothy Heffernan, Dana-Farber Cancer Institute, Boston, MA

From cancer genomes to tumours: Polygenic validation of human cancer mutations by in vivo tumorigenesis *
Su Kit Chew, Wellcome Trust Sanger Institute, Hinxton, England

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer *
Suet Leung, University of Hong Kong, Hong Kong, China

Break

Session 3: Functional Genomics II

Session Chairperson: David A. Largaespada, University of Minnesota, Minneapolis, MN
11:15 a.m.-12:45 p.m.

Uncovering cancer genes and pathways using unbiased, forward genetic screens 
David A. Largaespada

Translational genomics using population-based tumor models
Murray O. Robinson, AVEO Pharmaceuticals, Inc., Cambridge, MA

Characterisation of BRAF and NRAS models of zebrafish melanoma through exome sequencing *
Jennifer Yen, Wellcome Trust Sanger Institute, Hinxton, England

Cancer genome based multigenic models of colon cancer in Drosophila *
Erdem Bangi, Mount Sinai School of Medicine, New York, NY

Lunch on own / Free time

Session 4: Functional Genomics III

Session Chairperson: Lynda Chin, University of Texas MD Anderson Cancer Center, Houston, TX
2:30 p.m.-4:30 p.m.

Measuring the modeling life-death decisions in single cells
Peter K. Sorger, Harvard Medical School, Boston, MA

Translating the cancer genome
Lynda Chin

Genetic mining of the cancer genome: New entry points for anti-cancer therapy
Thomas (Trey) F. Westbrook, Baylor College of Medicine, Houston, TX

Optimizing molecularly-targeted cancer therapy using functional genomics *
Trever Bivona, University of California, San Francisco, CA

A Sleeping Beauty transposon mutagenesis screen suggests involvement of the imprinted Dlk1-Dio3 domain in hepatocellular carcinoma development *
Jesse Riordan, University of Iowa, Iowa City, IA

Poster Session A / Reception

4:30 p.m.-6:30 p.m.

• View titles and presenters in this session

Monday, October 17

Continental Breakfast

Keynote Presentation 2

Genomic determinants of malignant progression in pancreatic cancers
Douglas Hanahan, Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland

Session 5: Target Validation and Biology

Session Chairperson: Frank McCormick, University of California, San Francisco, CA
9:00 a.m.-11:00 a.m.

Recurrent gene fusions in prostate cancer: Implications for personalized medicine
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI

Targeting the undruggable: Lessons from Ras
Frank McCormick

Identification of high-value targets for oncology drug discovery
Markus Warmuth, H3 Biomedicine, Cambridge, MA

Functional characterization of WAC, a candidate tumor suppressor gene identified by transposon-based genetic screens for intestinal tumors in mice *
Caitlyn Conboy, University of Minnesota, Minneapolis, MN

Viability screens in leukemic and breast cancer cells with pooled lentiviral shRNA libraries identify potential therapeutic targets and synergistic lethal interactions *
Alex Chenchik, Cellecta, Inc., Mountain View, CA

Lunch on Own / Free Time

Session 6: Hot Topics

Session Chairperson: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA
1:00 p.m.-3:00 p.m.

Chemical and mechanical cues regulate signaling to drive malignancy
Valerie M. Weaver, University of California, San Francisco, CA

Diversity in breast cancer: Mechanisms and clinical relevance 
Kornelia Polyak

Variants in the germline genome that confer large risk of several cancers, including ovarian cancer and gliomas
Kári Stefánsson, deCODE genetics, Reykjavik, Iceland

RetroSeq: A tool to discover somatic insertion of retrotransposons *
Elena Helman, Harvard-MIT Health Sciences & Technology, Cambridge, MA

Selection of somatic mtDNA mutations in cancer development *
Estella Chen-Quin, Kennesaw State University, Kennesaw, GA

Break

Session 7: Defining the Clinical Path Hypothesis

Session Chairperson: Joe W. Gray, Oregon Health and Science University Knight Cancer Institute, Portland, OR
3:30 p.m.-5:00 p.m.

Models and processes to facilitate preclinical to clincal translation
Joe W. Gray

Developing genomic signatures into clinically actionable markers: Lessons from glioblastoma
Cameron W. Brennan, Memorial Sloan-Kettering Cancer Center, New York, NY

Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer – SU2C-001 *
Michael Barrett, Translational Genomics Research Institute, Phoenix, AZ

Next-generation diagnostics: Expanding clinical actionability of the cancer genome *
Alex Parker, Foundation Medicine Inc., Cambridge, MA

Poster Session B / Reception

5:00 p.m.-7:00 p.m.

• View titles and presenters in this session

Tuesday, October 18

Continental Breakfast

Keynote Presentation 3

8:00 a.m.-9:00 a.m.

The genetic basis for cancer therapeutics: The opportunity and the challenge
William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA

Session 8: Genomics in Clinical Trial Design

Session Chairperson: William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA
9:00 a.m.-11:00 a.m.

Clinical trials in early-stage cancer patients: Future opportunities and challenges
Peter Blume-Jensen, Metamark Genetics, Cambridge, MA

The ALK story: A new paradigm for the development of targeted therapies in NSCLC
Alice T. Shaw, Massachusetts General Hospital Cancer Center, Boston, MA

Integrated “omics” profiles for patient stratification
Anne-Lise Børresen-Dale, Institute for Cancer Research, Oslo, Norway

Personalized oncology through integrative high-throughput sequencing: A pilot study *
Sameek Roychowdhury, University of Michigan, Ann Arbor, MI

Identification of predictive biomarkers and development of patient stratification assay for co-targeting mTOR and AKT *
Theresa Zhang, Merck, Boston, MA

Departure